Why Is Celularity Stock Gaining Thursday?

Reported Earlier: Celularity And MuseCell Innovations Expand U.S. Manufacturing Collaboration, With Potential For $300M+ In Purchases Over Five Years

Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa

Celularity shares are trading higher after the company announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells at Celularity’s Florham Park, New Jersey facility.

Celularity To Begin U.S. Production Of MuseCell Innovations' Dezawa MuseCells At Its New Jersey Facility

The initial program is designed to establish manufacturing capability for MCI-authenticated DMC preparations. Under the MCI platform, a preparation is authenticated as a DMC product through perinatal, bone marrow or